MIG AG

MIG Verwaltungs AG is a Munich-based venture capital firm that focuses on investing in small and medium-sized enterprises across various industries, with a particular emphasis on life sciences and technology. Established in 2004, the firm targets investments in sectors such as artificial intelligence, machine learning, quantum technology, digitalization, medical technology, digital health, and biopharmaceuticals. MIG AG primarily invests in companies located in Germany, Austria, and Switzerland, with a minimum investment threshold of €0.1 million. The firm typically holds its investments for a duration of four to eight years before seeking an exit. Through its strategic investments, MIG AG aims to foster innovation and contribute to advancements in technology and healthcare.

Klaus Feix Ph.D

Venture Partner

Matthias Guth

Venture Partner

Oliver Kahl

Principal

Andreas Kastenbauer

Venture Partner

Jürgen Kosch

General Partner

Kromayer, Matthias

General Partner

Frederick Michna

Principal

Motschmann, Michael

General Partner

Thierauf, Axel

Venture Partner

Fei Tian

Principal

77 past transactions

Mbiomics

Series A in 2023
mbiomics is a biotechnology company.

NavVis

Venture Round in 2021
Bridging the gap between the physical and digital world, NavVis enables service providers and enterprises to capture and share the built environment as photorealistic digital twins. Our SLAM-based mobile mapping systems generate high-quality data with survey-grade accuracy at speed and scale. And with our digital factory solutions, users are equipped to make better operational decisions, boost productivity, streamline business processes, and improve profitability. Based in Munich, Germany, with offices in the United States and China, NavVis has customers worldwide in the surveying, AEC, and manufacturing industries. For more information, visit www.navvis.com.

GoBolt

Series B in 2021
Founded in 2017, GoBolt is a technology company building the first sustainable and vertically integrated supply chain network that partners with merchants to deliver a complete end-to-end customer experience. By operating as an extension of each merchant’s team, GoBolt provides reliable warehousing, pick and pack, shipping, and last mile delivery. With a growing network of warehouses across North America and a suite of proprietary apps designed and supported by an in-house engineering team, GoBolt unlocks enhanced transparency and control for merchants. The company’s focus on customer-centricity is further driven by a deep commitment to sustainability. GoBolt’s investment in its electric vehicle fleet and sustainability partnerships is a testament to the company’s mission to provide carbon neutral deliveries. For more information, visit GoBolt.com.

iOmx Therapeutics

Series B in 2021
iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the Company has already identified a number of novel targets and analyzed their mode of action. The Company was founded on the successful concept of cancer immune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Immune resistance of tumors is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. Reactivating the host immune response by neutralizing these negative interactions is the idea behind cancer immune-checkpoint therapy.

KEWAZO

Series A in 2021
KEWAZO is digitizing construction with robotics and data analytics. We integrate robotic platforms on-site to enable digital services. In scaffolding, our robotic material hoist LIFTBOT saves up to 44% of labor costs, addresses labor shortage, and improves safety. By having our robots on-site, we collect operational data and provide it to our customers in the form of a data analytics platform, enabling more proactive management of both individual projects and companies overall.

AMSilk

Series C in 2021
AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.

GoBolt

Venture Round in 2021
Founded in 2017, GoBolt is a technology company building the first sustainable and vertically integrated supply chain network that partners with merchants to deliver a complete end-to-end customer experience. By operating as an extension of each merchant’s team, GoBolt provides reliable warehousing, pick and pack, shipping, and last mile delivery. With a growing network of warehouses across North America and a suite of proprietary apps designed and supported by an in-house engineering team, GoBolt unlocks enhanced transparency and control for merchants. The company’s focus on customer-centricity is further driven by a deep commitment to sustainability. GoBolt’s investment in its electric vehicle fleet and sustainability partnerships is a testament to the company’s mission to provide carbon neutral deliveries. For more information, visit GoBolt.com.

Liva Healthcare

Series B in 2021
Liva Healthcare is an innovative digital health coaching platform for scalable lifestyle and disease management. Winner of 'Health IT Firm of the Year' at the HealthInvestor Awards 2018 and 'Healthtech Innovators of the Year - Europe' at the Global Health & Pharma Awards 2018, Liva Healthcare is used by public healthcare, private insurance and pharma companies including NHS England and AXA PPP Healthcare. Liva Healthcare’s platform facilitates ongoing personalized health coaching through an intuitive app, building a strong bond between coach, GP, and patient. Its focus lies on tackling chronic illnesses, such as Type 2 diabetes, obesity, and heart disease by driving behavior change. The app is multilingual across several languages, proven to work efficiently across all socio-economic backgrounds, and is capable of engaging groups normally hard to reach. It is based upon nine to 18 months of continuous patient engagement to make new habits and behaviors stick. One coach can manage 500 patients per year simultaneously without the loss of patient outcomes. Implementation time from the get-go is normally within weeks and the platform is available as a white-label SaaS platform or as a turn-key solution, dependent on client specifications. Liva Healthcare has offices in Copenhagen, Denmark, and London, UK.

German Bionic

Series A in 2020
German Bionic is backed by renowned international technology investors such as Samsung Catalyst Fund, Storm Ventures, and MIG, which is also invested in Covid-19 vaccine developer BioNTech. The company and its products are regularly featured in top-tier publications and are the recipients of numerous awards including the German Entrepreneur Award, the Land of Ideas Award, the Automatica Award as well as a nomination for Hannover Messe’s coveted Hermes Award. The German Bionic Cray X is the world’s first connected exoskeleton. Linked to the Smart Factory, it self-learns to reinforce lifting movements and prevent incorrect posture, thus becoming an intelligent link between humans and machines. In doing so, it delivers data that underscores its ability to protect the health of workers, measurably reduce the risk of accidents, and thereby make quantifiable improvements to work processes.

Innatera

Seed Round in 2020
Innatera is a trailblazing developer of ultra-low power intelligence for sensors. Incorporated in 2018 as a spin-off from the Delft University of Technology, it develops a line of neuromorphic processors that mimic the mechanisms the brain uses for sensory perception. Using a radically new continuous-time analog-mixed signal processing architecture, Innatera’s chips allow sensor data to be processed 100x faster and with up to 500x lesser energy than with conventional processors.

Efficient Energy

Venture Round in 2020
Efficient Energy GmbH is an innovative manufacturer and system supplier of environmentally friendly refrigeration technology, based in Feldkirchen near Munich, Germany. The company developed the Bluezero-technology, which uses water as a refrigerant and and thereby entirely avoids fluorinated refrigerants (HFCs). Efficient Energy helps its customers overcome the increasing regulatory challenges of refrigeration technology, and offers them long-term, clean, safe and efficient solutions with its eChiller model range. The eChiller chilled water units are ideally suited for process cooling, machine cooling and the cooling of technical equipment and data centres and provide cooling capacities from 35 kW to 120 kW, depending on the model. The company cooling systems provide outstanding cost efficiency and low CO2 footprint to its customers. The pioneering technology has also been noticed by politics and the media, and has received multiple awards. These include among others the European Business Award for the Environment 2018/2019 from the European Comission, the Red Herring Europe Top 100 in 2020, TOP 3 Deloitte Technology Fast 50 in 2021.

KEWAZO

Seed Round in 2020
KEWAZO is digitizing construction with robotics and data analytics. We integrate robotic platforms on-site to enable digital services. In scaffolding, our robotic material hoist LIFTBOT saves up to 44% of labor costs, addresses labor shortage, and improves safety. By having our robots on-site, we collect operational data and provide it to our customers in the form of a data analytics platform, enabling more proactive management of both individual projects and companies overall.

Biocrates Life Sciences

Venture Round in 2019
Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, and analysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably.

IQM Quantum Computers

Seed Round in 2019
IQM is the pan-European leader in building quantum computers. IQM delivers on-premises quantum computers for supercomputing data centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique application-specific, co-design approach. IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is also building a quantum computer in Germany. This computer will be integrated into an HPC supercomputer to create a quantum accelerator for future scientific research. IQM has over 190+ employees with offices in Paris, Madrid, Munich, and Espoo.

CYNORA

Series C in 2019
cynora GmbH develops and manufactures organic electronics. The company develops organic light-emitting diodes, blue OLED emitters systems, and organic solar cells that enable reduction in power consumption of OLED devices. It offers materials that are able to convert triplet excitons into light via Thermally Activated Delayed Fluorescence (TADF) to reduce electrical stress within the OLED and caters to AMOLED markets. The company was founded in 2008 and is headquartered in Bruchsal, Germany.

Liva Healthcare

Series A in 2019
Liva Healthcare is an innovative digital health coaching platform for scalable lifestyle and disease management. Winner of 'Health IT Firm of the Year' at the HealthInvestor Awards 2018 and 'Healthtech Innovators of the Year - Europe' at the Global Health & Pharma Awards 2018, Liva Healthcare is used by public healthcare, private insurance and pharma companies including NHS England and AXA PPP Healthcare. Liva Healthcare’s platform facilitates ongoing personalized health coaching through an intuitive app, building a strong bond between coach, GP, and patient. Its focus lies on tackling chronic illnesses, such as Type 2 diabetes, obesity, and heart disease by driving behavior change. The app is multilingual across several languages, proven to work efficiently across all socio-economic backgrounds, and is capable of engaging groups normally hard to reach. It is based upon nine to 18 months of continuous patient engagement to make new habits and behaviors stick. One coach can manage 500 patients per year simultaneously without the loss of patient outcomes. Implementation time from the get-go is normally within weeks and the platform is available as a white-label SaaS platform or as a turn-key solution, dependent on client specifications. Liva Healthcare has offices in Copenhagen, Denmark, and London, UK.

Efficient Energy

Venture Round in 2019
Efficient Energy GmbH is an innovative manufacturer and system supplier of environmentally friendly refrigeration technology, based in Feldkirchen near Munich, Germany. The company developed the Bluezero-technology, which uses water as a refrigerant and and thereby entirely avoids fluorinated refrigerants (HFCs). Efficient Energy helps its customers overcome the increasing regulatory challenges of refrigeration technology, and offers them long-term, clean, safe and efficient solutions with its eChiller model range. The eChiller chilled water units are ideally suited for process cooling, machine cooling and the cooling of technical equipment and data centres and provide cooling capacities from 35 kW to 120 kW, depending on the model. The company cooling systems provide outstanding cost efficiency and low CO2 footprint to its customers. The pioneering technology has also been noticed by politics and the media, and has received multiple awards. These include among others the European Business Award for the Environment 2018/2019 from the European Comission, the Red Herring Europe Top 100 in 2020, TOP 3 Deloitte Technology Fast 50 in 2021.

KONUX

Series B in 2019
KONUX GmbH, founded in 2014 and based in Munich, Germany, develops Industrial Internet of Things (IIoT) solutions that integrate smart sensor systems with artificial intelligence analytics. The company specializes in enhancing railway operations, offering a range of services including switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and predictive maintenance. KONUX's solutions enable real-time monitoring of infrastructure conditions and improve operational efficiency, capacity, and reliability in railway and industrial applications. The company has attracted significant investment, raising over $50 million and expanding its presence across Europe and Asia. Recognized by the World Economic Forum as one of the world's most innovative start-ups, KONUX is committed to transforming railway mobility for a sustainable future.

NavVis

Series C in 2018
Bridging the gap between the physical and digital world, NavVis enables service providers and enterprises to capture and share the built environment as photorealistic digital twins. Our SLAM-based mobile mapping systems generate high-quality data with survey-grade accuracy at speed and scale. And with our digital factory solutions, users are equipped to make better operational decisions, boost productivity, streamline business processes, and improve profitability. Based in Munich, Germany, with offices in the United States and China, NavVis has customers worldwide in the surveying, AEC, and manufacturing industries. For more information, visit www.navvis.com.

GWA Hygiene

Venture Round in 2018
You can already profit from the Internet of Things (IOT) with the hygiene monitoring solutions by GWA Hygiene. With their solution you can capture your hand disinfection and (soon to come) your surface disinfection processes. They will equip your disinfectant / soap dispenser with their sensor technology. They will install a monitor to display your station's data and link the job groups via their attachable transponders. The data can be stored either on your in-house server, or their secure cloud server. Their software toolbox helps you analyze your processes and additionally facilitates everyday logistical tasks, such as filling the dispensers with disinfectant or replacing defective devices.

Efficient Energy

Venture Round in 2018
Efficient Energy GmbH is an innovative manufacturer and system supplier of environmentally friendly refrigeration technology, based in Feldkirchen near Munich, Germany. The company developed the Bluezero-technology, which uses water as a refrigerant and and thereby entirely avoids fluorinated refrigerants (HFCs). Efficient Energy helps its customers overcome the increasing regulatory challenges of refrigeration technology, and offers them long-term, clean, safe and efficient solutions with its eChiller model range. The eChiller chilled water units are ideally suited for process cooling, machine cooling and the cooling of technical equipment and data centres and provide cooling capacities from 35 kW to 120 kW, depending on the model. The company cooling systems provide outstanding cost efficiency and low CO2 footprint to its customers. The pioneering technology has also been noticed by politics and the media, and has received multiple awards. These include among others the European Business Award for the Environment 2018/2019 from the European Comission, the Red Herring Europe Top 100 in 2020, TOP 3 Deloitte Technology Fast 50 in 2021.

advanceCOR

Venture Round in 2018
advanceCOR is a clinical drug developing company that focuses on therapeutics and diagnostics for heart and vascular diseases. Its products include Revacept, a human Fc fusion protein, which prevents the local activation of platelets at sites of vascular injury; COR-2, a recombinant protein that interferes with the generation of foam cells; and COR-3, a recombinant protein, which specifically binds to atherosclerotic plaques, and then bi-specifically binds to circulating progenitor cells to trap the endogenously occurring progenitor cells for accelerated plaque healing.

KEWAZO

Seed Round in 2018
KEWAZO is digitizing construction with robotics and data analytics. We integrate robotic platforms on-site to enable digital services. In scaffolding, our robotic material hoist LIFTBOT saves up to 44% of labor costs, addresses labor shortage, and improves safety. By having our robots on-site, we collect operational data and provide it to our customers in the form of a data analytics platform, enabling more proactive management of both individual projects and companies overall.

KONUX

Series B in 2018
KONUX GmbH, founded in 2014 and based in Munich, Germany, develops Industrial Internet of Things (IIoT) solutions that integrate smart sensor systems with artificial intelligence analytics. The company specializes in enhancing railway operations, offering a range of services including switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and predictive maintenance. KONUX's solutions enable real-time monitoring of infrastructure conditions and improve operational efficiency, capacity, and reliability in railway and industrial applications. The company has attracted significant investment, raising over $50 million and expanding its presence across Europe and Asia. Recognized by the World Economic Forum as one of the world's most innovative start-ups, KONUX is committed to transforming railway mobility for a sustainable future.

BioNTech

Series A in 2018
BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. It contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates.

Siltectra

Series B in 2017
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.

Hemovent

Series A in 2017
​​​Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop an innovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.

Efficient Energy

Venture Round in 2017
Efficient Energy GmbH is an innovative manufacturer and system supplier of environmentally friendly refrigeration technology, based in Feldkirchen near Munich, Germany. The company developed the Bluezero-technology, which uses water as a refrigerant and and thereby entirely avoids fluorinated refrigerants (HFCs). Efficient Energy helps its customers overcome the increasing regulatory challenges of refrigeration technology, and offers them long-term, clean, safe and efficient solutions with its eChiller model range. The eChiller chilled water units are ideally suited for process cooling, machine cooling and the cooling of technical equipment and data centres and provide cooling capacities from 35 kW to 120 kW, depending on the model. The company cooling systems provide outstanding cost efficiency and low CO2 footprint to its customers. The pioneering technology has also been noticed by politics and the media, and has received multiple awards. These include among others the European Business Award for the Environment 2018/2019 from the European Comission, the Red Herring Europe Top 100 in 2020, TOP 3 Deloitte Technology Fast 50 in 2021.

AFFiRiS

Venture Round in 2017
AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions.

LXP Group

Series A in 2017
LXP Group develops LX-Process. The LX-Process cracks 2G biomass and can readily be adapted for large-scale 2G ethanol manufacturing but is also inversely scalable, enabling economic retrofit of smaller, decentralized biogas plants. Also, the LX-Process eliminates a principle hurdle faced in bio-processing, namely the presence / concentration of inhibitors, which are formed in all existing 2G pre-treatment methods.

Siltectra

Series B in 2017
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.

KONUX

Series A in 2017
KONUX GmbH, founded in 2014 and based in Munich, Germany, develops Industrial Internet of Things (IIoT) solutions that integrate smart sensor systems with artificial intelligence analytics. The company specializes in enhancing railway operations, offering a range of services including switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and predictive maintenance. KONUX's solutions enable real-time monitoring of infrastructure conditions and improve operational efficiency, capacity, and reliability in railway and industrial applications. The company has attracted significant investment, raising over $50 million and expanding its presence across Europe and Asia. Recognized by the World Economic Forum as one of the world's most innovative start-ups, KONUX is committed to transforming railway mobility for a sustainable future.

AFFiRiS

Venture Round in 2016
AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions.

Siltectra

Series B in 2016
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.

KONUX

Series A in 2016
KONUX GmbH, founded in 2014 and based in Munich, Germany, develops Industrial Internet of Things (IIoT) solutions that integrate smart sensor systems with artificial intelligence analytics. The company specializes in enhancing railway operations, offering a range of services including switch monitoring, asset monitoring, rolling stock monitoring, anomaly detection, and predictive maintenance. KONUX's solutions enable real-time monitoring of infrastructure conditions and improve operational efficiency, capacity, and reliability in railway and industrial applications. The company has attracted significant investment, raising over $50 million and expanding its presence across Europe and Asia. Recognized by the World Economic Forum as one of the world's most innovative start-ups, KONUX is committed to transforming railway mobility for a sustainable future.

Hemovent

Series A in 2016
​​​Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop an innovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.

NavVis

Series B in 2015
Bridging the gap between the physical and digital world, NavVis enables service providers and enterprises to capture and share the built environment as photorealistic digital twins. Our SLAM-based mobile mapping systems generate high-quality data with survey-grade accuracy at speed and scale. And with our digital factory solutions, users are equipped to make better operational decisions, boost productivity, streamline business processes, and improve profitability. Based in Munich, Germany, with offices in the United States and China, NavVis has customers worldwide in the surveying, AEC, and manufacturing industries. For more information, visit www.navvis.com.

Efficient Energy

Venture Round in 2015
Efficient Energy GmbH is an innovative manufacturer and system supplier of environmentally friendly refrigeration technology, based in Feldkirchen near Munich, Germany. The company developed the Bluezero-technology, which uses water as a refrigerant and and thereby entirely avoids fluorinated refrigerants (HFCs). Efficient Energy helps its customers overcome the increasing regulatory challenges of refrigeration technology, and offers them long-term, clean, safe and efficient solutions with its eChiller model range. The eChiller chilled water units are ideally suited for process cooling, machine cooling and the cooling of technical equipment and data centres and provide cooling capacities from 35 kW to 120 kW, depending on the model. The company cooling systems provide outstanding cost efficiency and low CO2 footprint to its customers. The pioneering technology has also been noticed by politics and the media, and has received multiple awards. These include among others the European Business Award for the Environment 2018/2019 from the European Comission, the Red Herring Europe Top 100 in 2020, TOP 3 Deloitte Technology Fast 50 in 2021.

Siltectra

Series B in 2015
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.

Protagen

Venture Round in 2014
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

NavVis

Series A in 2014
Bridging the gap between the physical and digital world, NavVis enables service providers and enterprises to capture and share the built environment as photorealistic digital twins. Our SLAM-based mobile mapping systems generate high-quality data with survey-grade accuracy at speed and scale. And with our digital factory solutions, users are equipped to make better operational decisions, boost productivity, streamline business processes, and improve profitability. Based in Munich, Germany, with offices in the United States and China, NavVis has customers worldwide in the surveying, AEC, and manufacturing industries. For more information, visit www.navvis.com.

Siltectra

Series A in 2014
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.

Isarna Therapeutics

Venture Round in 2014
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Isarna Therapeutics

Venture Round in 2014
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Ganymed Pharmaceuticals

Series E in 2013
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

SuppreMol

Series D in 2013
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Efficient Energy

Venture Round in 2013
Efficient Energy GmbH is an innovative manufacturer and system supplier of environmentally friendly refrigeration technology, based in Feldkirchen near Munich, Germany. The company developed the Bluezero-technology, which uses water as a refrigerant and and thereby entirely avoids fluorinated refrigerants (HFCs). Efficient Energy helps its customers overcome the increasing regulatory challenges of refrigeration technology, and offers them long-term, clean, safe and efficient solutions with its eChiller model range. The eChiller chilled water units are ideally suited for process cooling, machine cooling and the cooling of technical equipment and data centres and provide cooling capacities from 35 kW to 120 kW, depending on the model. The company cooling systems provide outstanding cost efficiency and low CO2 footprint to its customers. The pioneering technology has also been noticed by politics and the media, and has received multiple awards. These include among others the European Business Award for the Environment 2018/2019 from the European Comission, the Red Herring Europe Top 100 in 2020, TOP 3 Deloitte Technology Fast 50 in 2021.

Siltectra

Series A in 2013
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.

SuppreMol

Series D in 2012
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Siltectra

Seed Round in 2012
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.

NFON

Venture Round in 2012
NFON is a Munich, Germany-based provider of outsourced telephone systems. nfon's outsourced telephone systems, called IP Centrex, are offered as a complete package from a single source. Operated by a fully redundant, high-performance computer centre and with more than 100 functions, the solution is designed to enable companies of all sizes to save up to 50% percent of the costs for a conventional phone system.

AFFiRiS

Venture Round in 2011
AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions.

IDENT Technology

Venture Round in 2011
IDENT Technology AG provides technology solutions for working with e-fields in near-field communication and gesture controlled human-machine-interface. It markets its SKINPLEX technologies for detection, interaction, and identification applications in the capacitive near field and the gesture supported human-machine control applications in the form of licenses. The company offers SKINPLEX GestIC for gesture detection applications; SKINPLEX zeropower sensor system, a quasi powerless near-field transponder system for touchless sensing applications in rough environments; and SKINPLEX ultra-low-power proximity system, which provides the solution to wake-up and power down devices on the approach and the departure of the user. It serves consumer electronics, white good, building management, health care, telecommunication, gaming, toys, and automotive Industries. The company was founded in 2002 and is based in Wessling, Germany. (Fact find : "Augment standing with logogram AG, Instates the reality medium on functionality, If a employee base is within range, The Augment states 3 Investor groups, And all employee functions under Network Workings.")

Isarna Therapeutics

Venture Round in 2011
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

CYNORA

Series A in 2011
cynora GmbH develops and manufactures organic electronics. The company develops organic light-emitting diodes, blue OLED emitters systems, and organic solar cells that enable reduction in power consumption of OLED devices. It offers materials that are able to convert triplet excitons into light via Thermally Activated Delayed Fluorescence (TADF) to reduce electrical stress within the OLED and caters to AMOLED markets. The company was founded in 2008 and is headquartered in Bruchsal, Germany.

AMSilk

Series B in 2011
AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.

Efficient Energy

Venture Round in 2011
Efficient Energy GmbH is an innovative manufacturer and system supplier of environmentally friendly refrigeration technology, based in Feldkirchen near Munich, Germany. The company developed the Bluezero-technology, which uses water as a refrigerant and and thereby entirely avoids fluorinated refrigerants (HFCs). Efficient Energy helps its customers overcome the increasing regulatory challenges of refrigeration technology, and offers them long-term, clean, safe and efficient solutions with its eChiller model range. The eChiller chilled water units are ideally suited for process cooling, machine cooling and the cooling of technical equipment and data centres and provide cooling capacities from 35 kW to 120 kW, depending on the model. The company cooling systems provide outstanding cost efficiency and low CO2 footprint to its customers. The pioneering technology has also been noticed by politics and the media, and has received multiple awards. These include among others the European Business Award for the Environment 2018/2019 from the European Comission, the Red Herring Europe Top 100 in 2020, TOP 3 Deloitte Technology Fast 50 in 2021.

SuppreMol

Series C in 2010
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Corimmun

Series B in 2010
Corimmun is a clinical drug developing company located in Martinsried near Munich, Germany, and is focused on novel therapeutics and diagnostics for heart and vascular diseases. Corimmun's activities and experiences comprise all steps from research to drug development and commercialization.

immatics biotechnologies

Series C in 2010
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

IDENT Technology

Venture Round in 2010
IDENT Technology AG provides technology solutions for working with e-fields in near-field communication and gesture controlled human-machine-interface. It markets its SKINPLEX technologies for detection, interaction, and identification applications in the capacitive near field and the gesture supported human-machine control applications in the form of licenses. The company offers SKINPLEX GestIC for gesture detection applications; SKINPLEX zeropower sensor system, a quasi powerless near-field transponder system for touchless sensing applications in rough environments; and SKINPLEX ultra-low-power proximity system, which provides the solution to wake-up and power down devices on the approach and the departure of the user. It serves consumer electronics, white good, building management, health care, telecommunication, gaming, toys, and automotive Industries. The company was founded in 2002 and is based in Wessling, Germany. (Fact find : "Augment standing with logogram AG, Instates the reality medium on functionality, If a employee base is within range, The Augment states 3 Investor groups, And all employee functions under Network Workings.")

Biocrates Life Sciences

Venture Round in 2010
Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, and analysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably.

Isarna Therapeutics

Venture Round in 2010
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

PDC Biotech

Series A in 2010
PDC Biotech GmbH (PDC) is a private biopharmaceutical company developing innovative therapeutics for the treatment of preterm labour and primary dysmenorrhea, two areas of significant unmet medical need and large market potential. The primary focus for the company is the development of a pipeline of products which are antagonists of the receptor for prostaglandin F2α (FP receptor). PDC has licensed exclusive worldwide rights to a family of FP receptor antagonists from Theratechnologies Inc. (www.theratech.com) which include both peptides (compounds composed of at least two amino acids) and peptidomimetics (peptide-like compounds).

Protagen

Venture Round in 2009
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Sovicell

Venture Round in 2009
Sovicell is dedicated to providing trusted state-of-the-art ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicology) products and services that enable their customers to rapidly obtain accurate and reproducible pharmacokinetic data about their drug candidates or other test substances.

Ganymed Pharmaceuticals

Series D in 2008
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Efficient Energy

Seed Round in 2008
Efficient Energy GmbH is an innovative manufacturer and system supplier of environmentally friendly refrigeration technology, based in Feldkirchen near Munich, Germany. The company developed the Bluezero-technology, which uses water as a refrigerant and and thereby entirely avoids fluorinated refrigerants (HFCs). Efficient Energy helps its customers overcome the increasing regulatory challenges of refrigeration technology, and offers them long-term, clean, safe and efficient solutions with its eChiller model range. The eChiller chilled water units are ideally suited for process cooling, machine cooling and the cooling of technical equipment and data centres and provide cooling capacities from 35 kW to 120 kW, depending on the model. The company cooling systems provide outstanding cost efficiency and low CO2 footprint to its customers. The pioneering technology has also been noticed by politics and the media, and has received multiple awards. These include among others the European Business Award for the Environment 2018/2019 from the European Comission, the Red Herring Europe Top 100 in 2020, TOP 3 Deloitte Technology Fast 50 in 2021.

Corimmun

Series A in 2008
Corimmun is a clinical drug developing company located in Martinsried near Munich, Germany, and is focused on novel therapeutics and diagnostics for heart and vascular diseases. Corimmun's activities and experiences comprise all steps from research to drug development and commercialization.

Protagen

Venture Round in 2008
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

SuppreMol

Series B in 2008
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Protagen

Venture Round in 2008
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Isarna Therapeutics

Venture Round in 2007
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Sovicell

Series D in 2007
Sovicell is dedicated to providing trusted state-of-the-art ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicology) products and services that enable their customers to rapidly obtain accurate and reproducible pharmacokinetic data about their drug candidates or other test substances.

Biocrates Life Sciences

Series A in 2006
Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, and analysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably.

Protagen

Series B in 2006
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Isarna Therapeutics

Private Equity Round in 2005
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.